ArticleImmunologic research2026
ANKFN1 in skin fibroblasts may modulate mast cell activity and is associated with dupilumab response in atopic dermatitis.
Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAtopic dermatitis (AD) is a prevalent chronic inflammatory skin disease. Dupilumab is a new targeted drug used to treat moderate to severe AD. However, some patients with AD exhibit poor response to dupilumab treatment.
objectiveThis study aims to investigate the potential role and mechanisms of ANKFN1 in the development of resistance to dupilumab in AD.
methodsThis study conducted a comprehensive analysis of bulk RNA, single-cell RNA (scRNA-seq), and spatial transcriptome sequencing data. A prospective cohort of 54 AD patients treated with dupilumab was analyzed. Based on the SCORAD score, we measured whether the AD patients responded to 16 weeks of dupilumab treatment. By analyzing differentially expressed genes between the pre-treatment response group and the resistant group, drug resistance-associated genes were identified and externally validated in an independent dataset. Subsequently, biological function enrichment analysis, immune cells assessment, scRNA-seq analysis, and spatial transcriptomics were employed to investigate ANKFN1's biological functions, cellular localization, and association with the immune microenvironment. Additionally, we constructed a ceRNA regulatory network.
resultsFour key genes ANKFN1, HTR3A, HLA-DQA1, and ALOX15B were identified, with ANKFN1 exhibiting the strongest predictive efficacy (AUC = 0.938) and showing significantly upregulated expression in the resistant group, a finding confirmed in the validation cohort. High ANKFN1 expression positively correlated with resting mast cell infiltration levels and negatively correlated with immune stimulatory factors, chemokines, and IL-4/IL-13 pathway receptors (IL4R, IL13RA1, IL13RA2), suggesting its association with an immunosuppressive microenvironment. scRNA-seq analysis revealed ANKFN1 was specifically overexpressed in fibroblasts, particularly within the COL6A5⁺ fibroblast subpopulation. Spatial transcriptomics analysis further validated this finding. The ceRNA network suggested ANKFN1 may be regulated by the lncRNA NEAT1/miR-224 axis and transcription factors AR and GRHL2.
conclusionANKFN1 may be associated with dupilumab non-response and warrants further validation.
Indexed as
Identifiers
42062651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.